One of the most poorly publicised and understood areas of global pharma is falsified and counterfeit medicines. Historically, the focus on this topic has been on low value -... read more →
http://www.bioprocessintl.com/manufacturing/cell-therapies/the-potential-application-of-real‑time-release-testing-for-the-biomanufacture-of-autologous-cell‑based-immunotherapies/ Onco-immunotherapy is arguably the hottest area in biotech. Juno, Bluebird, AdaptImmune, Novartis to name a few, have all placed significant bets. However, manufacturing scale-up and robust business models for... read more →
IPAV is pleased to announce that key team members will be presenting at the Terra Pinn US Regenerative Medicine Congress in Washington DC, USA, attempting to ‘Demystify Regenerative Medicine Intellectual... read more →
Fundamentally, IPAV is in the business of accelerating patient cures. Therefore, our team is excited by the opportunities presented by the US 21st Century Cures Act, which positively impacts all... read more →
Clinical trial regulation can be intimidating. The regulation of regenerative medicines: cell, gene, immune and tissue engineered therapeutics can appear impossible. However, key members of the IPAV team, along with... read more →
IPAV wishes to congratulate one of its most charismatic and impactful Advisory Board members, Prof Jeff Karp on an extraordinary study evaluating a novel gel that provides targeted delivery of... read more →